X4 Pharmaceuticals EBITDA vs. Current Valuation
| XFOR Stock | USD 0.81 0.23 39.66% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -107.5 M | Current Value -102.1 M | Quarterly Volatility 35.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.78 | 0.87 |
|
|
For X4 Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of X4 Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well X4 Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between X4 Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of X4 Pharmaceuticals over time as well as its relative position and ranking within its peers.
XFOR |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of X4 Pharmaceuticals. If investors know XFOR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about X4 Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.08) | Revenue Per Share 0.003 | Return On Assets (0.40) | Return On Equity 0.2177 |
The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of XFOR that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
X4 Pharmaceuticals Current Valuation vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining X4 Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare X4 Pharmaceuticals value to that of its competitors to determine the firm's financial worth. X4 Pharmaceuticals is rated second in ebitda category among its peers. It is rated second in current valuation category among its peers . X4 Pharmaceuticals reported last year EBITDA of (107.52 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value X4 Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.XFOR Current Valuation vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
X4 Pharmaceuticals |
| = | (107.52 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
X4 Pharmaceuticals |
| = | 42.14 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
XFOR Current Valuation vs Competition
X4 Pharmaceuticals is rated second in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 86.5 Million. X4 Pharmaceuticals totals roughly 42.14 Million in current valuation claiming about 49% of equities under Health Care industry.
X4 Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in X4 Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, X4 Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of X4 Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of X4 Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -107.1 K | -101.7 K | |
| Interest Income | 3.3 M | 3.5 M | |
| Operating Income | -107.5 M | -102.1 M | |
| Income Before Tax | -101.1 M | -96 M | |
| Total Other Income Expense Net | 6.4 M | 6.8 M | |
| Net Loss | -86.8 M | -82.4 M | |
| Net Loss | -101.2 M | -96.1 M | |
| Income Tax Expense | 78 K | 74.1 K | |
| Net Interest Income | -1.7 M | -1.8 M | |
| Net Loss | -111.1 M | -105.6 M | |
| Non Operating Income Net Other | -2 M | -1.9 M | |
| Change To Netincome | 7.1 M | 6.9 M | |
| Net Loss | (0.57) | (0.60) | |
| Income Quality | 0.95 | 0.71 | |
| Net Income Per E B T | 1.00 | 1.12 |
XFOR Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on X4 Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of X4 Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the X4 Pharmaceuticals' important profitability drivers and their relationship over time.
Use X4 Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.X4 Pharmaceuticals Pair Trading
X4 Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your X4 Pharmaceuticals position
In addition to having X4 Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cannabis Thematic Idea Now
Cannabis
Equities that are involved in production and delivery of legal cannabis. This theme is designed for investors that are willing to accept higher levels of market risk inherited by cannabis production and distribution globally. The Cannabis theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cannabis Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.